



Pádraig Mac Lochlainn, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

1st February 2023

PQ: 2130/23

To ask the Minister for Health if the drug, phesgo, is available to patients in Ireland; and if he will make a statement on the matter. -Pádraig Mac Lochlainn

Dear Deputy Mac Lochlainn,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 2130/23), which you submitted to the Minister for Health for response.

Phesgo[®] is a fixed dose subcutaneous injection combination of two cancer medicines which are approved and funded by the HSE i.e. Trastuzumab and Pertuzumab. Phesgo[®] is a new combination formulation containing both drugs that can be administered subcutaneously as a fixed dose.

In December 2022 Phesgo[®] was approved for reimbursement under the Oncology Drug Management System (ODMS) for the following licensed indications:

- In combination with chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
and
- In combination with Docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

The approved indications set out are in line with the current Pertuzumab (Perjeta®) indications that have been approved for reimbursement under the ODMS'.

Yours sincerely,

A handwritten signature in cursive script, appearing to read 'Suzanne Doyle', written in black ink on a white background.

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service